The center was formed in 1974 by the merger of the American Oncologic Hospital, which was founded in 1904 as the first cancer hospital in the United States, and the Institute for Cancer Research, founded in 1927.
In 1967 a large wing of the hospital was constructed based on a design by Vincent G. Kling using steep slopes of poured concrete and roof tiles by Ludowici.
In 1995, Fox Chase also became a founding member of the National Comprehensive Cancer Network, an alliance of 21 of the nation's leading academic cancer centers.
The center was an independent, non-profit institution until it became part of TUHS on July 1, 2012. On December 15, 2011, Fox Chase Cancer Center and Temple University Health system signed an affiliation agreement. Under the agreement, Fox Chase has connected and extended its current operations into the adjoining 176-bed and 33-acre Jeanes Hospital, which is already a part of the Temple University Health System. Fox Chase is considered the "Cancer Hub" of the Temple University Health System.
The center has more than 2,400 employees and an operating budget of $300 million. Revenue has steadily increased from $509 million in 2019 to $817 million in 2024, with fiscal year 2025 closing in on nearly $1 billion. In fiscal year 2024, annual hospital admissions were nearly 3,500 and outpatient visits to physicians were nearly 144,000. In fiscal year 2025, more than 18,500 new patients were seen at Fox Chase, and the number of patients has increased by more than 110% over the last 4 years. According to the Pennsylvania Health Care Containment Council, Fox Chase ranked second in inpatient surgical cancer cases in the state despite having fewer inpatient beds, operating rooms, and intensive care unit beds than larger centers.
Fox Chase Cancer Center has earned national rankings of 33 in cancer and 19 in urology among the country’s top 50 hospitals in the 2024-2025 Best Hospitals rankings from U.S. News & World Report, which puts these programs in the top 4% nationally.
2023 American Nurses Association Magnet Award for Nursing Excellence. Fox Chase Cancer Center is one of 15 hospitals to receive the award six or more times.
2020 the Press Ganey's Guardian of Excellence Award for excellence in clinical care in outpatient services.
2018 Anna Marie Skalka is awarded the William Procter Prize for Scientific Achievement, given to scientists who have made an outstanding contribution to scientific research and demonstrated an ability to communicate this research to scientists in other disciplines
2000 Fox Chase became the first US cancer center and the first hospital in Pennsylvania to earn the American Nurses Association Magnet Award for Nursing Excellence .
1993 Beatrice Mintz produces the first mouse model of human melanoma, in which the disease resembles the human malignancy.
1991 Philip Tsichlis, Alfonso Bellacosa, and Joseph Testa clone the AKT1 and AKT2 genes - the first viral oncogenes described that inhibit programmed cell death.
1991 Timothy Yen discovers that a molecular motor controls the way human cells sort their chromosomes when cells divide during mitosis.
1982 William Mason and Jesse Summers demonstrate that the hepatitis B virus utilizes reverse transcription for genome replication, previously thought to be unique to retroviruses.
1981 Beatrice Mintz's laboratory is one of the first to introduce a cloned gene into fertilized mouse eggs and prove that it is retained in animals developing from those eggs, and is transmitted to their progeny.
1980 Discovery of the SCID mouse, a mouse strain with no natural immunity, by Melvin Bosma. The SCID mouse is an essential research tool in devising new treatments.
1979 Beatrice Mintz shows that a fatal genetic anemia of mice can be prevented in utero by injecting normal blood-forming stem cells into the fetus through a placental blood vessel.
1962 The first demonstration, by Robert P. Perry, that ribosomal RNA is synthesized in the nucleolus as a large precursor molecule that is subsequently processed into mature components.
1962 Beatrice Mintz's development of the first mammal comprising two genetically different cell populations in all tissues, as a tool for analyses of embryonic development and disease in mouse models.
↑Neefjes, J.; Groothuis, T. a. M.; Dantuma, N. P. (December 25, 2004). "[The 2004 Nobel Prize in Chemistry for the discovery of ubiquitin-mediated protein degradation]". Nederlands Tijdschrift voor Geneeskunde. 148 (52): 2579–2582. ISSN0028-2162. PMID15646859.